CEO Leen Kawas resigns after special committee finds she altered images in doctoral research; Mark Litton appointed CEO.

LeonaBio, Inc.

Special committee concluded Dr. Kawas altered images in her 2011 dissertation and at least four research papers co-authored as a WSU graduate student.
Mark Litton, Ph.D., MBA, appointed President and CEO and to the board; Rachel Lenington, MBA, appointed COO, effective Oct 18, 2021.
Severance: Kawas receives lump sum of $510,000 plus COBRA reimbursement for up to 18 months; retains options for 363,535 shares.
ATH-1017 patent does not cite altered-image papers; Phase 1a/b trial results reaffirmed as statistically significant per independent audit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.